Kymera Therapeutics (KYMR) Stock Forecast & Price Target $59.83 -0.63 (-1.04%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$59.84 +0.01 (+0.02%) As of 10/17/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kymera Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 21 Analyst RatingsSell1Hold1Buy19 Based on 21 Wall Street analysts who have issued ratings for Kymera Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 1 has given a hold rating, 17 have given a buy rating, and 2 have given a strong buy rating for KYMR. Consensus Price Target $62.744.86% Upside According to the 21 analysts' twelve-month price targets for Kymera Therapeutics, the average price target is $62.74. The highest price target for KYMR is $80.00, while the lowest price target for KYMR is $51.00. The average price target represents a forecasted upside of 4.86% from the current price of $59.83. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for KYMR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Analyst Ratings Over TimeTypeCurrent Forecast10/18/24 to 10/18/251 Month Ago9/18/24 to 9/18/253 Months Ago7/20/24 to 7/20/251 Year Ago10/19/23 to 10/18/24Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)Buy17 Buy rating(s)17 Buy rating(s)17 Buy rating(s)8 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)4 Hold rating(s)Sell1 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$62.74$59.95$59.11$49.00Forecasted Upside4.86% Upside17.18% Upside28.00% Upside5.58% UpsideConsensus RatingModerate BuyBuyBuyModerate Buy KYMR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History KYMR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Kymera Therapeutics Stock vs. The CompetitionTypeKymera TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.95 2.33 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside4.86% Upside1,357.67% Upside13.59% UpsideNews Sentiment RatingNeutral NewsSee Recent KYMR NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/17/2025Citigroup3 of 5 starsGeoff Meacham Not RatedBoost TargetBuy$60.00 ➝ $80.00+32.32%10/8/2025Weiss Ratings0 of 5 stars Reiterated RatingSell (D-)10/1/2025Oppenheimer2 of 5 starsJeff Jones Not RatedBoost TargetOutperform$53.00 ➝ $63.00+11.31%9/30/2025Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSrikripa DevarakondaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$53.00 ➝ $68.00+16.58%9/18/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew S. FeinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$60.00 ➝ $70.00+45.47%9/17/2025BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEtzer DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight$60.00+23.00%9/16/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian AbrahamsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$70.00+48.05%7/30/2025B. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy$60.00+37.30%7/15/2025The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy7/3/2025Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageOverweight$70.00+57.20% Get the Latest News and Ratings for KYMR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 6/26/2025BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJeet MukherjeeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$59.00+26.96%6/26/2025Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDerek ArchilaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$57.00 ➝ $53.00+17.82%6/25/2025Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKelly ShiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet TargetBuy$64.00+38.01%6/3/2025GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael SchmidtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$60.00+20.75%6/3/2025JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric JosephSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$57.00 ➝ $64.00+48.39%6/2/2025Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeNeutral ➝ Buy$51.00+17.86%5/20/2025Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAlex ThompsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$55.00+81.79%5/13/2025UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$72.00 ➝ $70.00+125.66%1/21/2025StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingS. LoganathanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight$60.00 ➝ $60.00+37.83%12/27/2024Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingOutperform$60.00 ➝ $60.00+42.79%12/6/2024BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingE. DaroutSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageMarket Perform$55.00+24.77%9/9/2024Leerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingF. KhurshidSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy8/26/2024Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingA. ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$65.00+36.04%2/27/2024Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOverweight$39.00 ➝ $56.00+27.88%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:26 AM ET. KYMR Forecast - Frequently Asked Questions What is Kymera Therapeutics' forecast for 2025? According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Kymera Therapeutics is $62.74, with a high forecast of $80.00 and a low forecast of $51.00. Should I buy or sell Kymera Therapeutics stock right now? 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There is currently 1 sell rating, 1 hold rating, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KYMR shares. Does Kymera Therapeutics's stock price have much upside? According to analysts, Kymera Therapeutics's stock has a predicted upside of 4.86% based on their 12-month stock forecasts. Has Kymera Therapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, Kymera Therapeutics's stock had 1 upgrade by analysts. What analysts cover Kymera Therapeutics? Kymera Therapeutics has been rated by research analysts at B. Riley, Barclays, Citigroup, HC Wainwright, Oppenheimer, Royal Bank Of Canada, Truist Financial, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Kymera Therapeutics more than its competitors? Analysts like Kymera Therapeutics more than other "medical" companies. The consensus rating for Kymera Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how KYMR compares to other companies. Stock Forecasts and Research Tools Related Companies Summit Therapeutics Stock Forecast Ascendis Pharma A/S Stock Forecast Dr. Reddy's Laboratories Stock Forecast Viatris Stock Forecast Roivant Sciences Stock Forecast BridgeBio Pharma Stock Forecast Moderna Stock Forecast Qiagen Stock Forecast Elanco Animal Health Stock Forecast Verona Pharma PLC American Depositary Share Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:KYMR) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
